Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 827 results for "bayer healthcare"

Bayer and Onyx report disappointing Phase III results of Nexavar in breast cancer
Pharma Letter

RESILIENCE trial shows Bayer, Onyx drug combo doesn't improve ...

It was announced yesterday that Bayer HealthCare Pharmaceuticals, a global specialty pharmaceutical company, and Onyx Pharmaceuticals (NASDAQ: ONXX), a biopharmaceutical company, have revealed results from an investigational Phase III trial of ... MedCity News, 18 hours ago
[x]  

99 images for bayer healthcare

OncLive, 4 days ago
Digital Journal, 6 days ago
Newz4U.net, 6 days ago
Drug Discovery and Development, 1 week ago
Animal Pharm News, 23 hours ago
Drug Discovery and Development, 4 days ago
Pharmafocus, 2 weeks ago
Yahoo! News Australia, 4 weeks ago
Pharmafocus, 1 month ago
Austin American Statesman, 3 weeks ago

New eye injection from Bayer boosts visual acuity in two-year diabetic macular edema study

Bayer HealthCare, part of German pharma group Bayer AG (ETR:BAYN), reported Friday data from a Phase III study showing that aflibercept solution for injection 2 mg resulted in a sustained enhancement from baseline in best corrected visual acuity ...
 MedCity News1 week ago FDA Approves Bayer's Eylea for Diabetic Macular Edema Treatment  ADVFN India1 hour ago BAYER : FDA Approves Bayer's Eylea for Diabetic Macular Edema Treatment  4 Traders2 hours ago
[x]  

Fight medical apartheid: While Indian pharma keeps drugs affordable, western MNCs can be blatantly discriminatory

Marijn Dekkers, chief executive officer of Bayer, shocked advocates of affordable healthcare by candidly stating that "We did not develop this medicine for Indians, we developed it for western patients who can afford it."
 Times of India2 months ago
Securities Technology Monitor

There's Something in the Water: Global Icon, Berocca®, Arrives on U.S. Soil with New Special Formula and Flavor

Excitement is bubbling up nationwide and it's all about the fizz. Today, Bayer HealthCare announces the nationwide arrival of Berocca - an energy support supplement in an effervescent tablet that, when dropped into a glass of water, unleashes a ...
 Individual.com21 hours ago
[x]  

Finacea Foam Phase III Results Announced

Bayer HealthCare announced positive results from a Phase III trial that evaluated a 15 percent foam formulation of its compound azelaic acid (AzA) for the topical treatment of inflammatory papules and pustules of rosacea. An AzA foam formulation is ...
 PharmaAsia2 days ago Bayer Announces Clinical Results of Azelaic Acid 15% Foam for Rosacea  MedEsthetics Magazine4 days ago Bayer HealthCare AG Release: Phase 3 Investigational Trial Of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints In Subjects With Papulopustular Rosacea  BioSpace5 days ago Phase III Investigational Trial of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints in Subjects with Papulopustular Rosacea  Reuters5 days ago
[x]  
RTTNews.com

Bayer announces encouraging results from Phase III diabetic macular edema trial

Bayer HealthCare has announced that in the Phase III VIVID-DME trial of aflibercept solution for injection into the eye for the treatment of vision impairment due to diabetic macular edema, or DME, aflibercept solution for injection 2mg, in both ...
 Individual.com1 week ago Bayer Q2 Profit Rises 13%  RTTNews.com1 hour ago Regeneron, Bayer release positive Phase III trial results of EYLEA to treat DME  Pharmaceutical Business Review1 week ago Bayer : Phase 3 Trial Results Show Improvement In Vision For People With DME  RTTNews.com1 week ago

Bayer HealthCare Launches The Timeline Project

Bayer HealthCare has launched a new online community and tool, The Timeline Project According to a release from the company, the project is intended to ignite a conversation among Millennial women, defined as women between the ages of 18 and 29, to ...
 Individual.com6 days ago Encouraging millennial women to develop life goals [Infographic]  Champion Newspapers6 days ago

Bayer/Amgen's Nexavar Does Not Show Resilience in Study

The HealthCare segment at Bayer ( BAYRY - Analyst Report ) and partner, Amgen ( AMGN - Analyst Report ), announced that their oncology drug Nexavar has performed disappointingly in a phase III study (RESILIENCE: n=537) on breast cancer. ...
 Zacks.com4 days ago
[x]  
Jutia Group

Amgen Inc (NASDAQ:AMGN) Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer

[at noodls] Whippany, NJ and South San Francisco, CA . Jul 25, 2014 Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary (NASDAQ:AMGN), today announced that an investigational Phase 3 trial . . . → Read More: Similar Articles: ...
 Vision Monday4 days ago Market Update: Amgen Inc (NASDAQ:AMGN) Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37  Jutia Group11 hours ago Stock Update: Amgen Inc (NASDAQ:AMGN) Amgen Announces Webcast of 2014 Second Quarter Financial Results  Jutia Group5 days ago
[x]  
Animal Pharm News

Bayer secures extra EU indications for Seresto

Bayer HealthCare Animal Health's pet fleaand tick collar Seresto pet parasiticide has added new indications in the EU. The product now officially provides interalia indirect protection for dogs against vector-borne diseases (VBDs) for upto seven ...
 Animal Pharm News23 hours ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less